- Home
- AEHL vs SNSE Comparison
AEHL vs SNSE Comparison
Compare AEHL & SNSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AEHL
- SNSE
- Stock Information
- Founded
- AEHL 1993
- SNSE 2005
- Country
- AEHL China
- SNSE United States
- Employees
- AEHL N/A
- SNSE N/A
- Industry
- AEHL Building Materials
- SNSE Biotechnology: Pharmaceutical Preparations
- Sector
- AEHL Industrials
- SNSE Health Care
- Exchange
- AEHL Nasdaq
- SNSE Nasdaq
- Market Cap
- AEHL 8.5M
- SNSE 9.3M
- IPO Year
- AEHL 2007
- SNSE 2021
- Fundamental
- Price
- AEHL $2.70
- SNSE $8.85
- Analyst Decision
- AEHL
- SNSE Strong Buy
- Analyst Count
- AEHL 0
- SNSE 3
- Target Price
- AEHL N/A
- SNSE $86.67
- AVG Volume (30 Days)
- AEHL 124.8K
- SNSE 13.3K
- Earning Date
- AEHL 05-01-2025
- SNSE 08-05-2025
- Dividend Yield
- AEHL N/A
- SNSE N/A
- EPS Growth
- AEHL N/A
- SNSE N/A
- EPS
- AEHL N/A
- SNSE N/A
- Revenue
- AEHL $98,773,000.00
- SNSE N/A
- Revenue This Year
- AEHL N/A
- SNSE N/A
- Revenue Next Year
- AEHL N/A
- SNSE N/A
- P/E Ratio
- AEHL N/A
- SNSE N/A
- Revenue Growth
- AEHL 36.99
- SNSE N/A
- 52 Week Low
- AEHL $1.79
- SNSE $5.00
- 52 Week High
- AEHL $256.40
- SNSE $17.40
- Technical
- Relative Strength Index (RSI)
- AEHL 52.28
- SNSE 67.07
- Support Level
- AEHL $2.33
- SNSE $7.62
- Resistance Level
- AEHL $2.75
- SNSE $8.98
- Average True Range (ATR)
- AEHL 0.25
- SNSE 0.70
- MACD
- AEHL 0.03
- SNSE 0.21
- Stochastic Oscillator
- AEHL 67.21
- SNSE 96.15
About AEHL Antelope Enterprise Holdings Limited
Antelope Enterprise Holdings Ltd operates in two reportable operating segments: 1) business management consulting, information system technology consulting services including the sales of software use rights for digital data deposit platforms and asset management systems, and online social media platform development and consulting, and 2) natural gas power generation, which was in the initial development stage. The business of the Company is engaged in the PRC and U.S.
About SNSE Sensei Biotherapeutics Inc.
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101 (VISTA), SNS-102 (VSIG4 ), SNS-103 (ENTPDase/CD39), SNS-201 (VISTAxCD28).